Serum Adenosine Deaminase and IL 6 as Inflammatory Marker in Rheumatoid Arthritis

Title: Serum Adenosine Deaminase and IL 6 as Inflammatory Marker in Rheumatoid Arthritis

Authors: Ravela Malathi, Prasad Veeragandham, Anindita Banerjee, Abhishek Chattopadhyay, Upal Banerjee, Sanjay Kothari

DOI: https://dx.doi.org/10.18535/jmscr/v5i4.147

Abstract

Background & Objectives: Rheumatoid arthritis (RA) is a prototypical inflammatory joint disease. The degree of inflammation is reflected in the extent of joint damage, which further has influence on the quality of life of patients with RA. Serum adenosine deaminase (ADA) and IL-6 have been previously proposed to predict disease activity in patients with RA. The aim of this study was to investigate the level of serum ADA and IL-6, and the relationship between ADA and IL-6 as disease activity markers, in a group of patients with RA and compared with healthy subjects.

Methods: Sixty two RA patients and forty six age and sex matched healthy controls were included in the study. ADA activity and IL-6 levels in serum were measured in all the subjects and correlated.

Results: Serum ADA level was found significantly higher among RA subjects with respect to controls (43.73 ± 19.74 versus 18.96 ± 4.83 U/L; P < 0.0001). Moreover, serum IL 6 levels were also increased in RA cases as compared to controls and were statistically significant (19.48 ± 9.81 versus 8.33 ± 4.89 U/L; P < 0.0001). However, no correlation was observed between serum ADA with serum IL 6 level (r = 0.528; P = 0.237) among RA subjects as well as in controls (r = 0.071; P = 0.615).

Conclusion: Study showed a correlation study in which serum ADA does not correlate with IL 6 levels which means that they are not inter-dependent on each other and their levels rise individually. However, further larger and well controlled studies are needed to establish its role as inflammatory marker.

Keywords: Adenosine deaminase, IL-6, rheumatoid arthritis, serum.

References

1. Samanta R, Shoukrey K, Griffiths R. Rheumatoid arthritis and anaesthesia. Anaesthesia 2011; 66:1146–59.

2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205–19.

3. Nalesnik M, Nikolic JM, Jandric S. Adenosine deaminase and C-reactive protein in diagnosing and monitoring of rheumatoid arthritis. Med GlasLjek Komore Zenicko-Doboj Kantona 2011; 8:163–8.

4. Goronzy JJ, Matteson EL, Fulbright JW, Warrington KJ, Chang-Miller A, Hunder GG, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004; 50:43–54.

5. Yazici Y, Abramson SB. Rheumatoid arthritis treatment and monitoring of outcomes-where are we [corrected] in 2007? Bull NYU HospJt Dis 2007; 65:300–5.

6. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res Ther 2005; 7:R796–806.

7. Karsdal MA, Woodworth T, Henriksen K, Maksymowych WP, Genant H, Vergnaud P, et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities. Arthritis Res Ther 2011; 13:215.

8. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease activity score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 2007; 66:1221–6.

9. Khemka VK, Bagchi D, Ghosh A, et al. Raised Serum Adenosine Deaminase Level in Nonobese Type 2 Diabetes Mellitus. Scientific World Journal 2013; 2013: 404320.

10. Hitoglou S, Hatzistilianou M, Gougous-tamou D, Athanassiadou F, Kotsis A, Catriu D. Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2001; 20(6):411-6.

11. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin- in human disease. Ann Intern Med 1998; 128: 127–137

12. Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. RheumatolInt 1993; 13: 45–51

13. Srirangan S, Choy EH. The Role of Interleukin 6 in the Pathophysiology of Rheumatoid Arthritis. Ther Adv Musculoskelet Dis 2010 Oct; 2(5): 247–256.

14. Giusti G, Galanti B. Colorimetric method. Adenosine deaminase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. 3rd edition. Weinheim, Germany: Verlag Chemie; 1984; 315–323.

15. Karsdal MA, Woodworth T, Henriksen K, Maksymowych WP, Genant H, Vergnaud P, et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis–current and future applications, limitations and opportunities. Arthritis Res Ther 2011; 13(2):215.

16. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 2007; 66(9):1221–6.

17. Klimek E, Skalska A, Kwasny-Krochin B, Surdacki A, Sulicka J, Korkosz M, et al. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm 2014; 2014: 681635.

18. Shrivastava AK, Singh HV, Raizada A, Singh SK, Pandey A, Singh N, et al. Inflammatory markers in patients with rheumatoid arthritis. Allergol Immunop-athol (Madr) 2015; 43(1):81–87.

19. Surekha RH, Madhavi G, Srikhant BMV, Jharna P, Rao URK, Jyothi A. Serum ADA and C-reactive Protein in Rheumatoid Arthritis. Int J Hum Genet 2006;6(3):195–98.

20. Sari RA, Taysi S, Yilmaz O, Bakan N. Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2003; 21(1):87–90.

21. Demir G, Borman P, Ayhan F, Ozgun T, Kaygısız F, Yilmez G. Serum Adenosine Deaminase Level is High But Not Related with Disease Activity Parameters in Patients with Rheumatoid Arthritis. Open Rheumatol J 2014; 8:24–28.

22. Haque SS, Kumar S, Kumari R, Kumar U, Saran A, Tanweeruddin M. Evaluation of Biochemical marker for the diagnosis of Rheumatoid arthritis. J Health Sciences 2014;04(01):187–92.

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search

Abstract

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles